Deutsche Märkte schließen in 1 Stunde 20 Minute

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
118,12-0,73 (-0,61%)
Ab 10:08AM EST. Markt geöffnet.

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road Dublin 4
Dublin D04 E5W7
353 1 634 7800


Leitende Angestellte

Mr. Bruce C. CozaddCo-Founder, Chairman & CEO2,45M13,66M1964
Ms. Reneé D. GaláPresident & COO1,13MN/A1972
Mr. Daniel N. Swisher Jr.Non-Executive Employee1,47MN/A1963
Dr. Robert Iannone M.D.Executive VP and Global Head of Research & Development1,08MN/A1967
Ms. Patricia CarrSenior VP, CFO, & Chief Accounting OfficerN/AN/A1972
Ms. Andrea N. Flynn Ph.D.VP & Head of Investor RelationsN/AN/AN/A
Ms. Neena M. Patil J.D.Executive VP & Chief Legal Officer331,61kN/A1976
Dr. George Christopher Eliades Ph.D.Senior VP of Corporate Development & Chief Transformation OfficerN/AN/A1971
Ms. Heidi MannaSenior VP & Chief People OfficerN/AN/A1971
Dr. Jed Black M.D.Senior Vice President of Sleep & CNS MedicineN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.


Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. It offers medicines products, including therapies for sleep disorders and epilepsy, and cancer treatment. The company's lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy and to treat idiopathic hypersomnia; Xyrem, for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. Its lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; and Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase. It has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Corporate Governance

Jazz Pharmaceuticals plcs ISS Governance QualityScore, Stand 1. März 2024, lautet 3. Die grundlegenden Scores sind Audit: 6, Vorstand: 3, Shareholderrechte: 3, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.